Corvus Cash vs Retained Earnings Analysis

CRVS Stock

USD 9.42 0.69 7.90%

Corvus Pharmaceuticals financial indicator trend analysis is way more than just evaluating Corvus Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corvus Pharmaceuticals is a good investment. Please check the relationship between Corvus Pharmaceuticals Cash and its Retained Earnings accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corvus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.

Cash vs Retained Earnings

Cash vs Retained Earnings Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corvus Pharmaceuticals Cash account and Retained Earnings. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Corvus Pharmaceuticals' Cash and Retained Earnings is -0.01. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Corvus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Corvus Pharmaceuticals' Cash and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of Corvus Pharmaceuticals are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Cash i.e., Corvus Pharmaceuticals' Cash and Retained Earnings go up and down completely randomly.

Correlation Coefficient

-0.01

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cash

Cash refers to the most liquid asset of Corvus Pharmaceuticals, which is listed under current asset account on Corvus Pharmaceuticals balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Corvus Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Corvus Pharmaceuticals account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Most indicators from Corvus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corvus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corvus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Corvus Stock please use our How to Invest in Corvus Pharmaceuticals guide.At this time, Corvus Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Enterprise Value is likely to gain to about 80.6 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 7.5 M in 2024.

Corvus Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Non Current Assets Total
Total Assets		0.54	0.61	0.63	0.79	0.89	0.77	0.76	-0.71	-0.43	0.75	0.7	-0.23	0.93	0.57	-0.15	0.1	0.67	0.43	0.17	0.93	-0.16	0.21	0.46	0.67	0.31
Short Long Term Debt Total	0.54		0.42	0.16	0.32	0.16	0.22	0.02	-0.51	0.26	0.15	0.52	0.41	0.65	-0.1	0.31	0.22	0.11	-0.12	0.24	0.64	-0.07	-0.31	-0.11	0.78	-0.1
Other Current Liab	0.61	0.42		0.87	0.75	0.59	0.71	0.67	-0.41	-0.51	0.7	0.42	-0.34	0.48	0.55	-0.36	-0.43	0.69	0.71	-0.35	0.48	0.01	0.35	0.53	0.57	0.57
Total Current Liabilities	0.63	0.16	0.87		0.75	0.73	0.74	0.87	-0.22	-0.82	0.84	0.22	-0.66	0.39	0.79	-0.67	-0.38	0.86	0.87	-0.28	0.38	-0.15	0.57	0.73	0.4	0.73
Total Stockholder Equity	0.79	0.32	0.75	0.75		0.8	0.99	0.83	-0.76	-0.56	0.68	0.77	-0.42	0.67	0.54	-0.28	-0.53	0.72	0.68	-0.47	0.67	0.28	0.33	0.6	0.68	0.39
Other Liab	0.89	0.16	0.59	0.73	0.8		0.83	0.93	-0.56	-0.68	0.83	0.55	-0.5	0.76	0.77	-0.37	-0.08	0.79	0.64	0.0	0.76	-0.08	0.46	0.74	0.5	0.41
Net Tangible Assets	0.77	0.22	0.71	0.74	0.99	0.83		0.87	-0.74	-0.61	0.68	0.74	-0.49	0.64	0.6	-0.33	-0.55	0.75	0.72	-0.49	0.64	0.29	0.41	0.66	0.63	0.41
Current Deferred Revenue	0.76	0.02	0.67	0.87	0.83	0.93	0.87		-0.43	-0.87	0.85	0.42	-0.73	0.55	0.87	-0.62	-0.32	0.84	0.86	-0.23	0.55	-0.02	0.63	0.81	0.38	0.56
Net Debt	-0.71	-0.51	-0.41	-0.22	-0.76	-0.56	-0.74	-0.43		0.01	-0.36	-1.0	-0.11	-0.78	-0.1	-0.19	0.24	-0.33	-0.17	0.22	-0.78	-0.38	0.09	-0.13	-0.73	0.07
Retained Earnings	-0.43	0.26	-0.51	-0.82	-0.56	-0.68	-0.61	-0.87	0.01		-0.64	-0.01	0.96	-0.14	-0.94	0.86	0.33	-0.78	-0.92	0.26	-0.14	0.19	-0.88	-0.84	-0.07	-0.7
Accounts Payable	0.75	0.15	0.7	0.84	0.68	0.83	0.68	0.85	-0.36	-0.64		0.35	-0.42	0.59	0.67	-0.49	-0.1	0.73	0.64	-0.01	0.59	-0.13	0.29	0.52	0.3	0.47
Cash	0.7	0.52	0.42	0.22	0.77	0.55	0.74	0.42	-1.0	-0.01	0.35		0.11	0.78	0.1	0.19	-0.25	0.33	0.18	-0.24	0.78	0.38	-0.09	0.14	0.74	-0.07
Other Assets	-0.23	0.41	-0.34	-0.66	-0.42	-0.5	-0.49	-0.73	-0.11	0.96	-0.42	0.11		0.07	-0.86	0.85	0.37	-0.65	-0.86	0.32	0.06	0.19	-0.91	-0.75	0.08	-0.69
Cash And Short Term Investments	0.93	0.65	0.48	0.39	0.67	0.76	0.64	0.55	-0.78	-0.14	0.59	0.78	0.07		0.33	0.17	0.2	0.4	0.19	0.24	1.0	0.03	-0.04	0.27	0.68	-0.03
Common Stock Shares Outstanding	0.57	-0.1	0.55	0.79	0.54	0.77	0.6	0.87	-0.1	-0.94	0.67	0.1	-0.86	0.33		-0.78	-0.12	0.8	0.88	-0.04	0.33	-0.31	0.88	0.85	0.17	0.68
Short Term Investments	-0.15	0.31	-0.36	-0.67	-0.28	-0.37	-0.33	-0.62	-0.19	0.86	-0.49	0.19	0.85	0.17	-0.78		0.27	-0.7	-0.8	0.21	0.17	0.35	-0.8	-0.59	0.09	-0.78
Non Current Liabilities Total	0.1	0.22	-0.43	-0.38	-0.53	-0.08	-0.55	-0.32	0.24	0.33	-0.1	-0.25	0.37	0.2	-0.12	0.27		-0.27	-0.54	0.99	0.2	-0.64	-0.28	-0.36	-0.18	-0.25
Other Current Assets	0.67	0.11	0.69	0.86	0.72	0.79	0.75	0.84	-0.33	-0.78	0.73	0.33	-0.65	0.4	0.8	-0.7	-0.27		0.77	-0.19	0.39	-0.28	0.66	0.77	0.5	0.83
Other Stockholder Equity	0.43	-0.12	0.71	0.87	0.68	0.64	0.72	0.86	-0.17	-0.92	0.64	0.18	-0.86	0.19	0.88	-0.8	-0.54	0.77		-0.46	0.19	0.02	0.83	0.82	0.19	0.69
Total Liab	0.17	0.24	-0.35	-0.28	-0.47	0.0	-0.49	-0.23	0.22	0.26	-0.01	-0.24	0.32	0.24	-0.04	0.21	0.99	-0.19	-0.46		0.25	-0.68	-0.22	-0.3	-0.15	-0.18
Total Current Assets	0.93	0.64	0.48	0.38	0.67	0.76	0.64	0.55	-0.78	-0.14	0.59	0.78	0.06	1.0	0.33	0.17	0.2	0.39	0.19	0.25		0.03	-0.04	0.27	0.67	-0.03
Short Term Debt	-0.16	-0.07	0.01	-0.15	0.28	-0.08	0.29	-0.02	-0.38	0.19	-0.13	0.38	0.19	0.03	-0.31	0.35	-0.64	-0.28	0.02	-0.68	0.03		-0.24	0.03	0.12	-0.52
Common Stock	0.21	-0.31	0.35	0.57	0.33	0.46	0.41	0.63	0.09	-0.88	0.29	-0.09	-0.91	-0.04	0.88	-0.8	-0.28	0.66	0.83	-0.22	-0.04	-0.24		0.81	0.01	0.69
Property Plant Equipment	0.46	-0.11	0.53	0.73	0.6	0.74	0.66	0.81	-0.13	-0.84	0.52	0.14	-0.75	0.27	0.85	-0.59	-0.36	0.77	0.82	-0.3	0.27	0.03	0.81		0.34	0.53
Property Plant And Equipment Net	0.67	0.78	0.57	0.4	0.68	0.5	0.63	0.38	-0.73	-0.07	0.3	0.74	0.08	0.68	0.17	0.09	-0.18	0.5	0.19	-0.15	0.67	0.12	0.01	0.34		0.13
Non Current Assets Total	0.31	-0.1	0.57	0.73	0.39	0.41	0.41	0.56	0.07	-0.7	0.47	-0.07	-0.69	-0.03	0.68	-0.78	-0.25	0.83	0.69	-0.18	-0.03	-0.52	0.69	0.53	0.13

Click cells to compare fundamentals

Corvus Pharmaceuticals Account Relationship Matchups

Corvus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	83.6M	85.5M	109.5M	68.2M	45.6M	68.5M
Other Current Liab	6.9M	7.6M	7.1M	7.5M	2.6M	2.5M
Total Current Liabilities	12.5M	13.4M	12.3M	12.1M	6.9M	9.7M
Total Stockholder Equity	71.1M	72.1M	97.2M	56.1M	38.7M	69.5M
Net Tangible Assets	71.1M	72.1M	97.2M	56.1M	64.5M	72.5M
Net Debt	(2.0M)	(14.1M)	(59.8M)	(10.6M)	(11.2M)	(11.8M)
Retained Earnings	(217.1M)	(223.1M)	(266.4M)	(307.7M)	(334.7M)	(318.0M)
Accounts Payable	2.4M	3.5M	1.6M	2.0M	1.5M	2.2M
Cash	5.2M	16.5M	63.5M	13.2M	12.6M	12.0M
Other Assets	513K	414K	236K	129K	1.0	0.95
Cash And Short Term Investments	78.0M	44.3M	69.5M	42.3M	27.1M	25.8M
Common Stock Shares Outstanding	29.3M	29.5M	41.9M	46.6M	48.0M	30.7M
Short Term Investments	72.8M	27.8M	6.0M	29.1M	14.5M	13.8M
Liabilities And Stockholders Equity	83.6M	85.5M	109.5M	68.2M	45.6M	68.5M
Non Current Liabilities Total	869K	2.3M	1.2M	2.6M	1.4M	0.0
Other Current Assets	486K	991K	1.3M	728K	744K	687.3K
Other Stockholder Equity	288.2M	295.3M	361.7M	364.4M	374.4M	230.8M
Total Liab	12.5M	13.4M	12.3M	12.1M	6.9M	6.5M
Total Current Assets	78.0M	44.3M	69.5M	42.3M	28.0M	26.6M
Property Plant Equipment	2.2M	3.8M	2.6M	3.6M	4.2M	3.0M
Property Plant And Equipment Net	2.3M	1.6M	3.2M	2.2M	1.4M	1.8M
Non Current Assets Total	5.7M	41.3M	40.0M	25.9M	17.6M	18.0M
Non Currrent Assets Other	3.3M	2.4M	2.5M	1.8M	89K	84.6K
Net Receivables	329K	86K	539K	633K	63K	59.9K
Capital Surpluse	208.4M	280.8M	288.2M	295.3M	339.6M	233.5M
Inventory	(815K)	(492K)	(667K)	(735K)	(661.5K)	(694.6K)
Property Plant And Equipment Gross	3.8M	2.6M	3.2M	2.2M	6.1M	3.4M
Accumulated Other Comprehensive Income	29K	4K	1.9M	(563K)	(967K)	(918.7K)
Net Invested Capital	71.1M	72.1M	97.2M	56.1M	38.7M	60.6M
Net Working Capital	69.1M	33.2M	61.6M	32.9M	21.1M	20.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Corvus Stock Analysis

When running Corvus Pharmaceuticals' price analysis, check to measure Corvus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corvus Pharmaceuticals is operating at the current time. Most of Corvus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corvus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corvus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corvus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC